vs
Apellis Pharmaceuticals, Inc.（APLS）与GoodRx Holdings, Inc.（GDRX）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是GoodRx Holdings, Inc.的1.0倍（$199.9M vs $194.8M），GoodRx Holdings, Inc.净利率更高（2.8% vs -29.5%，领先32.3%），GoodRx Holdings, Inc.同比增速更快（-1.9% vs -5.9%），GoodRx Holdings, Inc.自由现金流更多（$31.6M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -0.8%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
GoodRx是一家美国医疗健康企业，运营着远程医疗平台以及可免费使用的网站与移动应用，服务覆盖美国超75000家药店，可为用户追踪处方药价格、提供药品优惠折扣券，还支持用户在线问诊，获取部分品类药物的处方。
APLS vs GDRX — 直观对比
营收规模更大
APLS
是对方的1.0倍
$194.8M
营收增速更快
GDRX
高出4.0%
-5.9%
净利率更高
GDRX
高出32.3%
-29.5%
自由现金流更多
GDRX
多$45.9M
$-14.3M
两年增速更快
APLS
近两年复合增速
-0.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $194.8M |
| 净利润 | $-59.0M | $5.4M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | 11.6% |
| 净利率 | -29.5% | 2.8% |
| 营收同比 | -5.9% | -1.9% |
| 净利润同比 | -62.2% | -19.5% |
| 每股收益（稀释后） | $-0.40 | $0.02 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSGDRX
| Q4 25 | $199.9M | $194.8M | ||
| Q3 25 | $458.6M | $196.0M | ||
| Q2 25 | $178.5M | $203.1M | ||
| Q1 25 | $166.8M | $203.0M | ||
| Q4 24 | $212.5M | $198.6M | ||
| Q3 24 | $196.8M | $195.3M | ||
| Q2 24 | $199.7M | $200.6M | ||
| Q1 24 | $172.3M | $197.9M |
净利润APLSGDRX
| Q4 25 | $-59.0M | $5.4M | ||
| Q3 25 | $215.7M | $1.1M | ||
| Q2 25 | $-42.2M | $12.8M | ||
| Q1 25 | $-92.2M | $11.1M | ||
| Q4 24 | $-36.4M | $6.7M | ||
| Q3 24 | $-57.4M | $4.0M | ||
| Q2 24 | $-37.7M | $6.7M | ||
| Q1 24 | $-66.4M | $-1.0M |
营业利润率APLSGDRX
| Q4 25 | -25.6% | 11.6% | ||
| Q3 25 | 48.7% | 7.5% | ||
| Q2 25 | -18.6% | 13.2% | ||
| Q1 25 | -50.0% | 11.5% | ||
| Q4 24 | -12.3% | 9.2% | ||
| Q3 24 | -24.0% | 10.5% | ||
| Q2 24 | -14.7% | 9.9% | ||
| Q1 24 | -36.0% | 3.7% |
净利率APLSGDRX
| Q4 25 | -29.5% | 2.8% | ||
| Q3 25 | 47.0% | 0.6% | ||
| Q2 25 | -23.6% | 6.3% | ||
| Q1 25 | -55.3% | 5.4% | ||
| Q4 24 | -17.1% | 3.4% | ||
| Q3 24 | -29.2% | 2.0% | ||
| Q2 24 | -18.9% | 3.3% | ||
| Q1 24 | -38.5% | -0.5% |
每股收益（稀释后）APLSGDRX
| Q4 25 | $-0.40 | $0.02 | ||
| Q3 25 | $1.67 | $0.00 | ||
| Q2 25 | $-0.33 | $0.04 | ||
| Q1 25 | $-0.74 | $0.03 | ||
| Q4 24 | $-0.30 | $0.01 | ||
| Q3 24 | $-0.46 | $0.01 | ||
| Q2 24 | $-0.30 | $0.02 | ||
| Q1 24 | $-0.54 | $0.00 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $261.8M |
| 总债务越低越好 | — | $495.0M |
| 股东权益账面价值 | $370.1M | $616.3M |
| 总资产 | $1.1B | $1.4B |
| 负债/权益比越低杠杆越低 | — | 0.80× |
8季度趋势，按日历期对齐
现金及短期投资APLSGDRX
| Q4 25 | $466.2M | $261.8M | ||
| Q3 25 | $479.2M | $273.5M | ||
| Q2 25 | $370.0M | $281.3M | ||
| Q1 25 | $358.4M | $301.0M | ||
| Q4 24 | $411.3M | $448.3M | ||
| Q3 24 | $396.9M | $423.8M | ||
| Q2 24 | $360.1M | $524.9M | ||
| Q1 24 | $325.9M | $533.3M |
总债务APLSGDRX
| Q4 25 | — | $495.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $500.0M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSGDRX
| Q4 25 | $370.1M | $616.3M | ||
| Q3 25 | $401.2M | $600.7M | ||
| Q2 25 | $156.3M | $643.0M | ||
| Q1 25 | $164.2M | $654.3M | ||
| Q4 24 | $228.5M | $724.7M | ||
| Q3 24 | $237.1M | $696.4M | ||
| Q2 24 | $264.3M | $669.4M | ||
| Q1 24 | $266.7M | $631.1M |
总资产APLSGDRX
| Q4 25 | $1.1B | $1.4B | ||
| Q3 25 | $1.1B | $1.3B | ||
| Q2 25 | $821.4M | $1.3B | ||
| Q1 25 | $807.3M | $1.3B | ||
| Q4 24 | $885.1M | $1.4B | ||
| Q3 24 | $901.9M | $1.4B | ||
| Q2 24 | $904.5M | $1.5B | ||
| Q1 24 | $831.9M | $1.5B |
负债/权益比APLSGDRX
| Q4 25 | — | 0.80× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.69× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $32.9M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $31.6M |
| 自由现金流率自由现金流/营收 | -7.1% | 16.2% |
| 资本支出强度资本支出/营收 | 0.1% | 0.6% |
| 现金转化率经营现金流/净利润 | — | 6.06× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $164.4M |
8季度趋势，按日历期对齐
经营现金流APLSGDRX
| Q4 25 | $-14.2M | $32.9M | ||
| Q3 25 | $108.5M | $76.0M | ||
| Q2 25 | $4.4M | $49.6M | ||
| Q1 25 | $-53.4M | $9.4M | ||
| Q4 24 | $19.4M | $44.7M | ||
| Q3 24 | $34.1M | $86.9M | ||
| Q2 24 | $-8.3M | $9.7M | ||
| Q1 24 | $-133.0M | $42.6M |
自由现金流APLSGDRX
| Q4 25 | $-14.3M | $31.6M | ||
| Q3 25 | $108.3M | $74.3M | ||
| Q2 25 | $4.4M | $49.2M | ||
| Q1 25 | $-53.4M | $9.3M | ||
| Q4 24 | $19.3M | $44.6M | ||
| Q3 24 | — | $86.5M | ||
| Q2 24 | $-8.4M | $9.4M | ||
| Q1 24 | $-133.3M | $42.2M |
自由现金流率APLSGDRX
| Q4 25 | -7.1% | 16.2% | ||
| Q3 25 | 23.6% | 37.9% | ||
| Q2 25 | 2.5% | 24.2% | ||
| Q1 25 | -32.0% | 4.6% | ||
| Q4 24 | 9.1% | 22.4% | ||
| Q3 24 | — | 44.3% | ||
| Q2 24 | -4.2% | 4.7% | ||
| Q1 24 | -77.3% | 21.3% |
资本支出强度APLSGDRX
| Q4 25 | 0.1% | 0.6% | ||
| Q3 25 | 0.0% | 0.9% | ||
| Q2 25 | 0.0% | 0.2% | ||
| Q1 25 | 0.0% | 0.1% | ||
| Q4 24 | 0.0% | 0.1% | ||
| Q3 24 | 0.0% | 0.2% | ||
| Q2 24 | 0.0% | 0.1% | ||
| Q1 24 | 0.2% | 0.2% |
现金转化率APLSGDRX
| Q4 25 | — | 6.06× | ||
| Q3 25 | 0.50× | 67.94× | ||
| Q2 25 | — | 3.86× | ||
| Q1 25 | — | 0.85× | ||
| Q4 24 | — | 6.64× | ||
| Q3 24 | — | 21.91× | ||
| Q2 24 | — | 1.45× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
GDRX
| Prescription Transactions Revenue | $124.7M | 64% |
| Other | $44.4M | 23% |
| Subscription Revenue | $21.6M | 11% |
| Other Revenue | $4.1M | 2% |
